Medtech Leaders’ Post

A 35-year-old presents for a consultation for widespread, chronic plaque psoriasis that is recalcitrant to multiple therapies. He had an initial response to cyclosporine and MTX, but has had no response to biologics targeting TNF, IL-17A, or IL-23. He denies joint disease. He has no family history of disease. He has had multiple skin biopsies that showed an T cell predominant psoriasiform pattern without signs of malignancy. What is the best next step? Supported by independent educational grants from Janssen Biotech, Inc and UCB Don't miss this opportunity to expand your knowledge and join us at IDS 2024! Email courses@learnskin.com once you've completed this and two more microcourses for a big discount! https://bit.ly/4cuhrla #IDS2024 #IntegrativeDermatology #LearningOpportunity #ContinuingEducation

⚡️ FGFR inhibitors are shaping the future of precision medicine in urothelial carcinoma. Recent advancements, including erdafitinib’s FDA approval and promising combination regimens, highlight their growing role in targeted therapy for biomarker-selected patients. Expanding their use to earlier stages of disease remains a key challenge. #BladderCancer #PrecisionMedicine https://buff.ly/3VomVHU

Ivonescimab, a revolutionary bispecific antibody developed by Akeso Biopharma, merges PD-1 immunotherapy blockade with anti-VEGF angiogenesis inhibition in one innovative formulation. A pivotal Phase III (HARMONi-A trial) is currently underway, assessing ivonescimab combined with chemotherapy in EGFR-mutated, locally advanced, or metastatic non-squamous NSCLC patients who have progressed after third-generation EGFR TKI treatment. Enrollment is expected to conclude in the latter half of 2024. Tap into Expert Insights and Detailed Analysis with DelveInsight Business Research LLP's Exclusive Coverage of American Society of Clinical Oncology (ASCO) 2024! https://lnkd.in/gR77RGnt #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

Advancing HFpEF Management with Mineralocorticoid Receptor Antagonists The role of mineralocorticoid receptor antagonists (MRAs) in heart failure with preserved ejection fraction (HFpEF) has been a subject of ongoing debate. A recent randomized trial involving over 6000 patients with heart failure (HF) and left ventricular ejection fraction ≥40% revealed that patients treated with the MRA finerenone experienced fewer acute HF episodes compared to placebo over a median follow-up of 32 months. While the impact on worsening HF was modest, these findings align with results from a previous trial involving spironolactone, further supporting the therapeutic value of MRAs. For patients receiving optimal HF management, including diuretics, sodium-glucose co-transporter 2 inhibitors (SGLT2i), and possibly semaglutide, who continue to exhibit New York Heart Association class II to III HF symptoms, the addition of an MRA is now a recommended consideration. #HeartFailure #HFpEF #Cardiology #Pharmacy #ClinicalPharmacy #EvidenceBased

#SPMNOTES $SMMT $16.40 +4.14. DAC (dollar average cost) $7.35 (6.19.24). CHANGE EXIT TO "OPEN" FROM $16.00. OVERVIEW: ^ Initiate HARMONi-7, a Phase III Trial in First-Line PD-L1 High, Advanced NSCLC, in Early 2025 ^Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in a Randomized Phase III Clinical Trial in NSCLC ^Median PFS of 11.14 Months vs. 5.82 Months, Respectively, for Patients Receiving Ivonescimab vs. Pembrolizumab; PFS Improvement Was Observed Broadly in Patients Across Subgroups, including PD-L1 High and Low Expressing Tumors, Squamous and Non-Squamous Histologies ^Comparable Serious Treatment-Related Adverse Events and TRAE-Led Discontinuation Rates Were Observed; Serious TRAEs were 20.8% vs. 16.1%, Respectively, in Ivonescimab and Pembrolizumab Arms ^ Positive Perioperative NSCLC Phase II Data Also Featured in an Oral Presentation at WCLC 2024

Two years ago, the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPLWMiPB) granted approval for the first clinical trial of #OATD02. This marked a pivotal moment in our journey to advance innovative therapies in immunooncology 🔬   #OATD02, our dual arginase inhibitor, is currently in a Phase I trial involving patients with solid tumors. We are nearing the completion of dosing in a group of 6 patients at 20 mg. In January, following recommendations from the Safety Review Committee, we will make a critical decision regarding further dose escalation. This step will bring us closer to identifying the maximum tolerated dose or the recommended dose for Phase II as potentially effective, a milestone we expect to achieve in the coming year.   At #Molecure, we are proud of the progress we’ve made and remain committed to unlocking new possibilities in cancer treatment! 🚀

Early detection can save lives! As we observe National Skin Cancer and Melanoma Awareness Month, let's remind ourselves and others about the importance of regular skin checks and early detection. By being proactive about our skin health, we can improve outcomes and reduce the impact of these diseases. 🔍👩⚕️ 🩺 Medcare Pharma: Your Way to Cure Contact us: ☎️ | 1-866-4-MEDICINE 📧 | info@medcarepharma.care 🌐 | https://lnkd.in/gA9pPUVR #waytocure #skincancer #melanoma #nationalskincancer #awarenessmonth #clinicaltrialsupport #pharmacy #clinicaltrial #clinicalresearch #medicalresearch #clinicalstudies #clinicalstudy #healthcare #medcarepharma #researchstudies

Bristol Myers Squibb Adagrasib, a potent KRASG12C inhibitor, showed substantial enhancements in progression-free survival and notable tumor responses in patients with KRASG12C-mutated NSCLC who had been previously treated, as demonstrated in the Phase III KRYSTAL-12 trial. Despite its safety profile and effectiveness being reaffirmed, with a median PFS increase compared to docetaxel, it remains a crucial treatment choice for this patient group. Ongoing research in the KRYSTAL-7 trial explores its potential in combination therapies. Uncover Expert Insights and Comprehensive Analysis with DelveInsight Business Research LLP's Premier American Society of Clinical Oncology (ASCO) 2024 Coverage! https://lnkd.in/g4Xf7CsY #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #mCRPC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

JUST OUT, FDA approved osimertinib for adult patients with stage III non-small cell #LungCancer #NSCLC that is locally advanced and unresectable, specifically for those whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations This approval applies to patients whose disease has not progressed following platinum-based chemoradiation therapy. The approval was based on the LAURA trial, which showed osimertinib significantly improved progression-free survival (PFS) compared to placebo, with a median PFS of 39.1 months versus 5.6 months. https://lnkd.in/drQQ4Y83

🔍 Introducing Technetium Tc99m Sulfur Colloid Injection 🔍 Our Technetium Tc99m Sulfur Colloid Injection is designed for subcutaneous, intraperitoneal, intravenous, and oral diagnostic use. It aids in the localization of lymph nodes in breast cancer and melanoma, evaluates shunt patency, and supports imaging of the liver, spleen, and more. Why Choose Sulfur Colloid? ✅ Proven ✅ Trusted ✅ Safe Available by prescription only—consult your healthcare professional to see if it’s right for you. For detailed information, including indications, safety warnings, and usage, please refer to the full prescribing information. Your health and safety matter. Let’s ensure proper patient management with effective diagnostic tools. #Healthcare #Diagnostics #NuclearMedicine #PatientSafety LEVALIS PHARMA DMCC Pharmalucence